Modified DTPA molecule-based nanocolloid radiopharmaceuticals

Alexander S. Rogov, Viktor S. Skuridin, Elena Sergeevna Stasyuk, Natalia Valerievna Varlamova, Evgeny A. Nestwrov, Vladimir Leonidovich Sadkin, Ekaterina A. Ilina

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)


The researches 99mTc recovery process at presence of divalent Sn(II) were made to determine necessary and sufficient amount of Sn(II), which would provide its full reducibleness in the reaction mixture. That the solution of 99mTc eluate reacts directly with the solution of modified DTPA and SnCl2 the content of radiochemical impurity (RCI) of the unreduced 99mTc(VII) in the labeled nanocolloid is 2.7 %, while the yield of the nanocolloid with the size of 100 nm is approximately 80 %. The results of researches prove the nanocolloid actively gets into the lymphatic system after injection, thus indicating its functional usefulness.

Original languageEnglish
JournalJournal of Radioanalytical and Nuclear Chemistry
Publication statusAccepted/In press - 24 Sep 2014


  • Biopsy
  • DTPA
  • Nanocolloid materials
  • Pharmaceutical
  • Radiochemical

ASJC Scopus subject areas

  • Analytical Chemistry
  • Nuclear Energy and Engineering
  • Health, Toxicology and Mutagenesis
  • Pollution
  • Public Health, Environmental and Occupational Health
  • Spectroscopy
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Modified DTPA molecule-based nanocolloid radiopharmaceuticals'. Together they form a unique fingerprint.

Cite this